Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
Chun‐Jen Liu(National Taiwan University), Pei‐Jer Chen(National Taiwan University), Rey‐Heng Hu(National Taiwan University Hospital), Kuan-Lang Lai, Sheng‐Shun Yang(Taichung Veterans General Hospital), Cheng‐Yuan Peng(China Medical University), Ming‐Chin Yu, Deng‐Yn Lin(Chang Gung University), Wei‐Chen Lee(Chang Gung University), Long‐Bin Jeng(National Cancer Center), Cheng-Chung Wu(Taichung Veterans General Hospital), Stanley Shi-Chung Chang, Ching-Chih Lee(Buddhist Tzu Chi General Hospital), Hong-Zen Yeh(Taichung Veterans General Hospital), Pin-Wen Lin(National Cheng Kung University Hospital), Ming‐Chih Ho(National Taiwan University Hospital), K T Mok(Kaohsiung Veterans General Hospital), Po‐Huang Lee(E-Da Hospital)
Cited by 157
Related Papers
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653
Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men
|JNCI Journal of the National Cancer Institute|2005|569